PMV Pharmaceuticals Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
21.5%projected annual EPS growth
Analyst Coverage
4analysts covering
FY EPS (est.)
-$1.41next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 12 Nov 2026 |
| Q4 2026 and Full Year 2026 Earnings Release | 4 Mar 2027 |
Monitoring Framework
Key Performance Indicators
Overall Response Rate (ORR) in Platinum-Resistant/Refractory Ovarian Cancer Quarterly44.0%Target: Maintain or exceed 40% to support registrational discussions
Cash, Cash Equivalents, and Marketable Securities Quarterly93.5MTarget: Sufficient to fund operations through Q2 2027
Quarterly Net Loss Quarterly18MTarget: Under $20 million through disciplined R&D and G&A spending
Watch Items
- New Drug Application (NDA) Submission for RezatapoptTrigger: Submission target of Q1 2027Action: Complete enrollment of additional 20-25 platinum-resistant/refractory ovarian cancer patients and compile final Phase 2 PYNNACLE data.
- Cash Runway DepletionTrigger: Cash balance falling below $50 millionAction: Evaluate capital-raising options, including dilutive equity offerings, strategic partnerships, or licensing agreements before the Q1 2027 NDA submission.
Research as of 19 Jun 2026